|
|
|
| home > white papers > Data Technology as a Catalyst for Growth in the Life Sciences - AIGENPULSE |
|
|
 WHITE PAPERS |
|
|
AIGENPULSE
|
|
Data Technology as a Catalyst for Growth in the Life Sciences
|
|
The life sciences industry is changing at a rapid pace. The need to develop the next blockbuster is pushing current technologies and methodologies to the limit. Scientific advancement over the last decades was embossed with giant leaps in knowledge, however, the new reality is that smaller incremental gains need to be carved out with ever increasing investments. In order to survive, progress and prosper in this new reality, a holistic approach to getting the most of research data is crucial. In fact, it will likely be the difference of being in existence in 5-10 years or not. For those bold enough to step into an area they are unfamiliar with, huge rewards are waiting.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
2019 Pharmapack Awards
Pharmapack Europe have announced entries for the 2019 Pharmapack Awards are now open across both the ‘Exhibitor Innovation’ and ‘Health Products’ categories with a closing date of 30th November 2018. The Health Products category will include two winners with one for Patient-Centric Design – which is launched in partnership with HCPC Europe (Healthcare Compliance Packaging Council of Europe) – and a second introduced alongside Adelphe for Eco-design in health packaging and drug delivery devices. Pharmapack Europe have also announced that they’re accepting applications for the start-up hub which provides young start-up companies servicing the pharma industry with the benefit of valuable networking and learning opportunities at half the price of a regular stand.
More info >> |
|
 |
White Papers |
 |
|
Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections
IBT Bioservices
Introduction
Staphylococcus aureus (SA) is a ubiquitous, formidable
Gram-positive pathogen associated with skin and soft tissue, as well as
lifethreatening systemic infections. SA is a leading cause of hospital- and
community-associated infections worldwide, affecting humans and animals. The
wide range of pathologies reflects the diverse abilities of this microbe to
escape the innate and adaptive immune response using virulence factors. Since
its first emergence in the 1960s methicillin-resistant SA (MRSA) has become
endemic in hospitals and healthcare settings worldwide. In the 1990s, community
associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a
major global challenge.
More info >> |
|
 |
Industry Events |
 |
SMi Presents the 11th Adaptive Designs in Clinical Trials Conference 2019
1-2 April 2019, Holiday Inn Kensington Forum, London
SMi Group are proud to announce the 11th annual Adaptive
Designs in Clinical Trials conference and exhibition will return to London from
the 1st – 2nd April 2019. With the growing popularity in use and acceptance of
adaptive designs in clinical trials - demonstrated most recently with the new
FDA draft guidance on adaptive designs – there is a pressing need for a forum
which explores this increasingly normalized medical methodology.
More info >> |
|
|
|
